Ken Griffin
BDTX icon

Ken Griffin’s Black Diamond Therapeutics BDTX Stock Holding History

Ken Griffin’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
502,652
+77,193
+18% +$184K ﹤0.01% 7500
2025
Q4 		$1.03M Buy
+425,459
New +$1.51M ﹤0.01% 7326
2025
Q3 		– Sell
-185,272
Closed -$459K – 12766
2025
Q2 		$459K Buy
+185,272
New +$357K ﹤0.01% 8836
2024
Q4 		– Sell
-703,704
Closed -$2.02M – 14499
2024
Q3 		$3.06M Buy
703,704
+699,175
+15,438% +$3.8M ﹤0.01% 4744
2024
Q2 		$21.1K Sell
4,529
-6,557
-59% -$35.2K ﹤0.01% 12587
2024
Q1 		$56.2K Sell
11,086
-109,679
-91% -$442K ﹤0.01% 12063
2023
Q4 		$339K Buy
120,765
+101,994
+543% +$239K ﹤0.01% 8919
2023
Q3 		$53.9K Sell
18,771
-1,196,637
-98% -$4.41M ﹤0.01% 11677
2023
Q2 		$6.14M Buy
1,215,408
+657,637
+118% +$1.34M ﹤0.01% 3330
2023
Q1 		$1.05M Sell
557,771
-216,027
-28% -$496K ﹤0.01% 6662
2022
Q4 		$1.39M Buy
773,798
+733,149
+1,804% +$1.32M ﹤0.01% 6184
2022
Q3 		$69K Sell
40,649
-45,295
-53% -$140K ﹤0.01% 11399
2022
Q2 		$211K Buy
85,944
+42,856
+99% +$99.6K ﹤0.01% 10588
2022
Q1 		$119K Buy
43,088
+491
+1% +$1.79K ﹤0.01% 12092
2021
Q4 		$227K Buy
42,597
+971
+2% +$6.78K ﹤0.01% 11585
2021
Q3 		$352K Buy
41,626
+11,445
+38% +$113K ﹤0.01% 10706
2021
Q2 		$368K Buy
30,181
+13,062
+76% +$258K ﹤0.01% 10769
2021
Q1 		$415K Buy
+17,119
New +$462K ﹤0.01% 10084

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ken Griffin's BDTX Position: Q1 2026 in Review

Ken Griffin increased its Black Diamond Therapeutics (BDTX) stake by 18% in Q1 2026, buying an estimated $184K and bringing the position to 502,652 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #7500.

Ken Griffin first reported a position in BDTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $6.14M in Q2 2023. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Ken Griffin held 502,652 shares of Black Diamond Therapeutics worth $1.07M as of Q1 2026.
  • Ken Griffin bought 77,193 Black Diamond Therapeutics shares in Q1 2026, an estimated $184K.
  • Black Diamond Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7500 holding.
  • Ken Griffin first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Ken Griffin's Black Diamond Therapeutics position peaked at $6.14M in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.